WebbENABLE selected its first candidate – Juvabis’ apramycin programme – in October 2024. Mutabilis’ candidate MUT485 received candidate status in November 2024. Juvabis’ clinical candidate apramycin is currently evaluated in a Phase I randomised, double-blind, placebo-controlled single ascending dose study in healthy volunteers. Webb21 maj 2024 · Juvabis has a clinical candidate for the treatment of gram-negative systemic infections that sets itself apart from other candidates by a superior coverage of highly drug-resistant infections including all of …
Pharma Integrates Speakers 2024 - Life Science Integrates
Webb- Sven Hobbie of Juvabis - Mauro Sette of Medyria - Yaakov Benenson of Pattern BioSciences ... - Danuta Cichocka of Resistell - Peter Nestorov of Scailyte - Andrea Chicca of Synendos Therapeutics - Stefanie Flückiger-Mangual of tolremo Therapeutics - Amélie Beduer of Volumina Medical. More information about the Venture Leaders Life … WebbJuvabis is a startup company that designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance. The company has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the rbsa advisors india
Venturelab - World-class Startups. Swiss made.
WebbAt a glance Originator Aventis Developer Aventis; Juvabis Therapeutics Class Aminoglycosides; Antibacterials; Small molecules Mechanism of Action Protein … Webb6 apr. 2024 · Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates … Webb3 aug. 2024 · Juvabis aims to develop innovative formulations that can be used to treat chronic, rare, and orphan diseases. The second start-up pitching at our event was Inura Medical AG. Rafiq Hussain and Vanja Ivancevic, CEO and COO of Inura respectively, presented their innovative idea. rbs accessories